BARCELONA, April 19, 2012 /PRNewswire/ - Today Merck announced results demonstrating no difference in the rates of viral clearance between two anemia management strategies for patients with chronic

NEW YORK, Feb. 14, 2012 /PRNewswire/ -- Intellect Neurosciences, Inc.

LAKE FOREST, Ill., Jan.

MADISON, Wis., Dec.

Erythropoietin or EPO might be considered a "performance enhancing" substance for athletes, but new research published online in The FASEB Journal (http://www.fasebj.org) shows that these enhancements come at a high cost--increased risk of vascular problems in the brain.